Here's a Journal Watch that summarizes a study entitled “ Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial ” published in Future Oncology, 2022 . What was the need for the study? Prostate cancer cells require androgens, including testosterone or dihydrotestosterone (DHT), for their growth ( Figure 1 ). Androgen deprivation therapy (ADT) is a standard treatment to reduce testosterone levels and slow the growth of prostate cancer cells.
1,3 A combination of docetaxel and ADT has shown to significantly improve the overall survival in metastatic, hormone-sensitive prostate cancer (mHSPC) patients. 4 Additionally, darolutamide is an androgen-receptor inhibitor known to improve overall survival in nonmetastatic, castration-resistant prostate cancer patients. However, whether…
